In partnership with

Conferences

Disease Areas

Highlights from

EAN 2020

European Academy of Neurology

Virtual 23 - 26 May 2020

Articles

Letter from the Editor

Letter from the Editor

Alzheimer's Disease and Other Dementias

Non-Alzheimer’s disease pathophysiology in the elderly

Novel genetic association with resistance to ERC tau deposition

News on AD biomarkers

Diastolic dysfunction novel risk factor for cognitive impairment

Epilepsy

Avoidable epilepsy-related mortality remains high

How genetic testing can contribute to epilepsy management

Cenobamate effective in focal epilepsy

Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome

Prevalence of autoantibodies in epilepsy almost 10%

Parkinson's Disease

White matter matters in Parkinson’s disease

Sleep disorders mark PD progression

Long-term safety of ND0612 in idiopathic PD

Directional DBS superior to omnidirectional DBS

Stroke

Benefits of statins to prevent stroke outweigh risks

Extubation after thrombectomy: the sooner, the better

Thrombus location and length predictors of early neurological deterioration

Endovascular treatment in large vessel occlusion stroke patients treated with OAC

Early edoxaban may be safe after cardioembolic stroke

Headache and Pain

Small fibre pathology as biomarker for fibromyalgia

Migraine as a cyclical functional disorder

Reassuring real-world safety profile of 3 CGRP inhibitors

Long-term cardiovascular safety of erenumab

Real-world data for erenumab in Germany

Eptinezumab in chronic migraine and medication-overuse headache

Fremanezumab tolerability in cardiovascular patients with migraine

Effects of galcanezumab on health-related quality of life

Unmet needs and pipeline

Multiple Sclerosis

Imaging to evaluate remyelination and neuroprotection

MRI-based clustering of MS patients

Serum NfL predicts long-term clinical outcomes in MS

Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

High NEDA rates after 2 years of ocrelizumab

Two trials comparing relapsing MS treatments

Switching from natalizumab to moderate- versus high-efficacy DMT

Results of compounds in late stages of development

Alemtuzumab efficacy and safety data of over 9 years

Fampridine treatment results in routine clinical practice

Air pollution is a possible risk factor for MS

Neuromyelitis Optica Spectrum Disorder

Genetic association studies in NMOSD needed

Eculizumab in NMOSD: the PREVENT study

Long-term safety of satralizumab consistent with double-blind periods

Neuromuscular Disorders

Biomarkers predicting motor function in SMA

Sustained benefits of avalglucosidase alfa in late-onset Pompe disease

Efficacy and safety of rituximab in refractory MG corroborated

Top image: @ iStockPhoto: koto_feja

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

@eaneurology